Skip to NavigationSkip to content

First Paediatric Use Marketing Authorisation Granted

Published date: 

The European Commission has granted the first ever children’s medicine to hold a new Paediatric Use Marketing Authorisation (PUMA). The medicine called Buccolam is now specifically licensed to treat convulsions and epileptic seizures in children.
A PUMA will cover the appropriate formulation for the paediatric population. Once granted, the PUMA will benefit from ten years of market protection as a reward for the development.

This change is a leap forward in helping to improve the safety, quality and availability of children’s medicines in the EU.

The development of medicines for children also require a Paediatric Investigation Plan (PIP) which must discuss all paediatric subsets to be agreed by the Paediatric Committee.

If you require assistance with a Paediatric Use Marketing Authorisation or Paediatric Investigation Plan please contact us at or telephone +44 (0)1628 530554.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches